top of page

PSARLink by Mablink Bioscience

Our unique technology enables the design of ADCs with improved efficacy and better tolerability while unlocking the use of novel payloads

Next-generation antibody-drug conjugates
powered by the exclusive ​PSARLink™ platform 

MBK-103
our lead ADC candidate

  • Validated druggable target: FR⍺
​
  • Potential to address:
    • Ovarian Cancer,
    • Triple Negative Breast Cancer,
    • Non-Small Cell Lung Cancer,
    • Colorectal Cancer
​
  • Exatecan (anti topo-I) as payload
     
  • Excellent pharmacological profile thanks to PSARLink™ 
 
Clinical trials planned to start in 2024 based on promising preclinical results.
MBK-103

News

All News

Upcoming events

  • World ADC
    World ADC
    World ADC
    Mon, Oct 16
    San Diego
    Oct 16, 9:00 AM PDT – Oct 19, 4:50 PM PDT
    San Diego, 1380 Harbor Island Dr, San Diego, CA 92101, USA
    Oct 16, 9:00 AM PDT – Oct 19, 4:50 PM PDT
    San Diego, 1380 Harbor Island Dr, San Diego, CA 92101, USA
    Accelerate Your Antibody-Drug Conjugate Pipeline to Become a Front-Line Treatment
    Share
    Learn more
  • ESMO 2023
    ESMO 2023
    ESMO 2023
    Fri, Oct 20
    Madrid
    Oct 20, 9:00 AM PDT – Oct 24, 7:00 PM PDT
    Madrid, Av. del Partenón, 5, 28042 Madrid, Spain
    Oct 20, 9:00 AM PDT – Oct 24, 7:00 PM PDT
    Madrid, Av. del Partenón, 5, 28042 Madrid, Spain
    Discover our pioneering approach, a diversified pipeline of novel ADCs based on the proprietary hydrophilic polysarcosine drug-linker platform.
    Share
    Learn more
  • BIO-Europe
    BIO-Europe
    BIO-Europe
    Mon, Nov 06
    München
    Nov 06, 9:00 AM CST – Nov 08, 9:00 AM CST
    München, Am Messeturm, 81829 München, Allemagne
    Nov 06, 9:00 AM CST – Nov 08, 9:00 AM CST
    München, Am Messeturm, 81829 München, Allemagne
    Share
    Learn more
bottom of page